HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Profit from the Pros – Zacks Free Email Newsletter
Our free email newsletter is filled with timely stock picks and market commentary. Sign up for free. Already on board? Check out the archive.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


JNJ: Johnson & Johnson - Stock News Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Company News |  Zacks Commentary
JOHNSON & JOHNSON (NYSE)
JNJ 62.31 0.37 (0.60%) Vol.  16,300,134 16.00 CST

Nov 20, 2009 Sector Update: Health Care Shares Lower in Pre-Market Session - Merck Approved for Elonva by CHMP in EU
Nov 19, 2009 The Deal LLC Announces Winners of the Second Annual Most Admired Corporate Dealmakers Awards
Nov 18, 2009 UAE launches campaign to tackle diabetes pandemic
Nov 18, 2009 Social Media Training from 4A's Socially Speaking Webinar Nov. 24 at 3pm ET to Feature Eric Schwartzman on Social Media Strategy
Nov 18, 2009 Depomed Promotes William Callahan to Vice President of Operations
Nov 18, 2009 StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc.
Nov 17, 2009 RevMed Locks in Acclaimed MRI Pioneer on Eve of National ProductDebut
Nov 16, 2009 Sector Update: Health Care Shares Mixed in Pre-Market Session - Report Questions Effectiveness of Merck's Zetia
Nov 16, 2009 Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Nov 16, 2009 Neuropathic Pain Drug Market Will Increase From $6 Billion in 2008 to $9.7 Billion in 2018
Nov 16, 2009 Hozumi Named GM Of Japan Unit Of Accuray
Nov 13, 2009 Human Pheromone Sciences Announces Third Quarter Results
Nov 13, 2009 Accuray Hires General Manager for Japan
Nov 13, 2009 Stryker Strikes Acquisition Deals
Nov 12, 2009 Trading Outlook for BioElectronics Corporation Issued by StockPreacher.com
 
ZACKS COMMENTARY FOR JNJ
Nov 13, 2009 Zacks Blog: DexCom Loss Narrows
Nov 12, 2009 Zacks Blog: Stryker Strikes Acquisition Deals
Nov 11, 2009 Zacks Blog: Isis Loss Widens
Nov 11, 2009 Zacks Blog: Wright Receives FDA Approval
Nov 11, 2009 Zacks Blog: Zacks Analyst Blog Highlights: Boston Scientific Corporation, Johnson & Johnson, Medtronic Inc., Abbott Laboratories and St. Jude Medical Inc.
Nov 10, 2009 Zacks Blog: BSX Settles, Lowers Results
Nov 09, 2009 Zacks Blog: Big Pharma and Biotech
Nov 09, 2009 Zacks Blog: Alkermes Moves to Loss but Beats
Nov 05, 2009 Zacks Blog: American Medical Reports Strong
Nov 05, 2009 Zacks Blog: SurModics Misses
Nov 05, 2009 Zacks Blog: Zacks Bull and Bear of the Day Highlights: Novatel Wireless, The Corporate Executive Board, Automatic Data Processing, Johnson & Johnson and Kraft Foods
Nov 04, 2009 Zacks Blog: ADP Sees 203,000 Jobs Lost

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research